培美曲塞二钠和多西他赛对非小细胞肺癌化疗患者血清Survivin、VEGF水平的影响  

Effects of Pemetexed and Docetaxel on the Serum Levels of Survivin and VEGF in Patients with Non-small Cell Lung Cancer

作　　者：王青[1] 孙开宇[2] 张文利[2] 朱维款 范路欣 

机构地区：[1]潍坊医学院临床医学院,山东潍坊261000 [2]潍坊市人民医院呼吸内科一区,山东潍坊261000 [3]青岛大学临床医学院,山东青岛266023

出　　处：《肿瘤药学》2017年第2期230-234,共5页Anti-Tumor Pharmacy

摘　　要：目的观察培美曲塞二钠和多西他赛对晚期非小细胞肺癌化疗患者血清Survivin、VEGF水平的影响。方法选择晚期非小细胞肺癌患者60例,选用随机数字表法将其随机分为两组,A组(n=30)采用培美曲塞二钠+顺铂方案治疗;B组(n=30)采用多西他赛+顺铂方案治疗。比较两组临床疗效、血清Survivin、VEGF水平、不良反应及2年生存情况。结果 A组与B组临床疗效的差异无统计学意义(23.3%vs.16.7%,χ~2=0.47,P=0.79);A组血清Survivin、VEGF水平降低程度大于B组(t=-4.44,4.16,P<0.01);A组Ⅰ~Ⅱ度不良反应中白细胞、血小板减少及恶心呕吐的发生率较B组明显降低(χ~2=1.19,P<0.05),A组2年生存率为36.7%,B组为26.7%,两组比较差异无统计学意义(χ~2=0.69,P=0.40)。结论培美曲塞与多西他赛分别联合顺铂治疗非小细胞肺癌的疗效无明显差异,化疗后血清Survivin和VEGF水平均降低,A组优于B组,提示培美曲塞联合顺铂治疗肺癌更能有效延缓癌细胞的生长、转移。Objective To explore the effects of pemetrexed or docetaxel on the serum levels of survivin and VEGF in patients with non- small cell lung cancer （NSCLC）. Methods 60 cases of patients with non-small cell lung cancer were selected. They were randomly divided into two groups. Group A （30 cases） were treated with pemetrexed and cisplatin, while group B （30 cases） were treated with doeetaxel and cisplatin. Compare the clinical efficacy, the serum levels of survivin and VEGF, adverse reactions and two years survival rate between the two groups. Results There were no significant differences between group A and group B in curative effect （23.3% vs. 16.7%, x^2=0-47, P=0.79）. The levers of survivin and VEGF in group A were significantly lower than those in group B （t=-4.44, 4.16, P 〈 0.01）. The inci- dence rates of complications involving grade I^II of lencopenia, thromboeypenia and nausea and vomiting in group A were significantly less than those in group B （x^ 2=1-19, P 〈 0.05）. The two-year survival rate in group A （36.7%） was slightly higher than in group B （26.7%）, but there was no statistical difference between the two groups （x^ 2=0.69, P=0.40）. Conclusion Pemetrexed combined with eisplatin did not had superior efficacy to doeetaxed combined with eisplatin for non-small cell lung cancer. After completion of chemotherapy, the levers of snr- vivin and VEGF in group A was significantly lower than those in group B, suggesting that the treatment of pemetrexed combined with eispla- tin could effectively delay the metastasis.

关 键 词：培美曲塞 多西他赛 非小细胞肺癌 SURVIVIN VEGF 

分 类 号：R734.2[医药卫生—肿瘤]